Overview

Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2018-10-11

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and the best dose of Hsp90 inhibitor AUY922 when given together with pemetrexed disodium in treating patients with previously treated stage IV non-small cell lung cancer. Hsp90 inhibitor AUY922 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cell, either by killing the cells or stopping them from dividing. Giving Hsp90 inhibitor AUY922 together with pemetrexed disodium may kill more tumor cells

Phase:

Phase 1

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

National Cancer Institute (NCI)
Novartis
Translational Research in Oncology

Treatments:

Pemetrexed